The company's robust pipeline was another focal point of discussion, with plans to initiate Phase 3 trials for NBI-568, an M4 agonist, and osavampator, an AMPA PAM, in the first half of 2025.

Merck's current discounted valuation, and robust pipeline advancements, which tripled over the past 3+ years, present a compelling long-term investment opportunity. Its strong business performance ...

According to Emirates NBD Research, the value of UAE project investment remained robust in 2024 ... with a potential further $659 billion in the pipeline ($336 in budgeted projects and $323 ...

New York, USA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Myocardial Infarction Clinical Trial Pipeline Appears Robust With 45+ Key Pharma Companies Actively Working in the Therapeutics Segment ...

New York, USA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- 5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...